To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.
Latest action · Jun 23, 2023 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJun 21, 2023
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
This bill requires the Food and Drug Administration (FDA) to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy, including how to request support from the FDA for related investigational use exemptions.
Cosponsors 2
Members who signed on, in the order they did. All signed on Jun 21, 2023.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-IA | Mariannette Miller-Meeks | Original | Jun 21, 2023 |
| D-CA | Ro Khanna | Original | Jun 21, 2023 |
Actions 3
Everything that happened, newest first.
- Jun 23, 2023Referred to the Subcommittee on Health.
- Jun 21, 2023Introduced in House
- Jun 21, 2023Referred to the House Committee on Energy and Commerce.
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Jun 21, 2023Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.